A carregar...
EGFR and myosin II inhibitors cooperate to suppress EGFR‐T790M‐mutant NSCLC cells
An acquired mutation (T790M) in the epidermal growth factor receptor (EGFR) accounts for half of all relapses in non‐small cell lung cancer (NSCLC) patients who initially respond to EGFR kinase inhibitors. In this study, we demonstrated for the first time that EGFR‐T790M interacts with the cytoskele...
Na minha lista:
| Publicado no: | Mol Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528336/ https://ncbi.nlm.nih.gov/pubmed/22366308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.02.001 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|